Literature DB >> 12391507

Current status of thrombolysis for peripheral arterial occlusive disease.

Kenneth Ouriel1.   

Abstract

Acute peripheral arterial occlusion occurs as a result of thrombosis or embolism. A reduction in the prevalence of rheumatic heart disease accounts for a shift in the frequency of embolic to thrombotic occlusions. Also, a dramatic increase in the number of lower extremity arterial bypass graft procedures explains the predominance of graft occlusions in most recent series of patients with acute limb ischemia. While open surgical procedures remain the gold standard in the treatment of peripheral arterial occlusion, thrombolytic agents have been employed as an alternative to primary surgical revascularization in patients with acute limb ischemia. Systemic administration of thrombolytic agents, while effective for small coronary artery clots, fails to achieve dissolution of the large peripheral arterial thrombi. Catheter-directed administration of the agents directly into the occlusive thrombus is the only means of effecting early recanalization. Prior to 1999, urokinase was the sole agent used in North America for peripheral arterial indications, but the loss of the agent from the marketplace forced clinicians to turn to alternate agents, specifically alteplase and reteplase. Interest in the use of platelet glycoprotein inhibitors and mechanical thrombectomy devices also rose, coincident with the loss of urokinase from the marketplace. Most clinicians welcome the predicted return of urokinase to the marketplace. New investigative trials should be organized and executed to answer some of the remaining questions related to thrombolytic treatment of peripheral arterial disease. Foremost in this regard remains the question of which patients are best treated with percutaneous thrombolytic techniques and which are best treated with primary operative intervention. Ultimately, however, the thrombolytic agents are but one tool in the armamentarium of the vascular practitioner. This review is directed at providing the practicing clinician with the basic fund of knowledge necessary when determining the most appropriate intervention in a particular patient with peripheral arterial occlusion, be it thrombolytic therapy, percutaneous mechanical thrombectomy, primary surgical revascularization, or a combination of the three.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391507     DOI: 10.1007/s10016-001-0318-y

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  8 in total

1.  Purification and characterization of a novel fibrinolytic protease from Fusarium sp. CPCC 480097.

Authors:  Bin Wu; Licheng Wu; Daijie Chen; Zhijun Yang; Minyu Luo
Journal:  J Ind Microbiol Biotechnol       Date:  2009-01-14       Impact factor: 3.346

2.  The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.

Authors:  Yacine Boulaftali; Lamia Lamrani; Marie-Catherine Rouzaud; Stéphane Loyau; Martine Jandrot-Perrus; Marie-Christine Bouton; Benoît Ho-Tin-Noé
Journal:  Thromb Haemost       Date:  2012-03-08       Impact factor: 5.249

3.  ADAMTS13 exerts a thrombolytic effect in microcirculation.

Authors:  Marilena Crescente; Grace M Thomas; Melanie Demers; Jaymie R Voorhees; Siu Ling Wong; Benoit Ho-Tin-Noé; Denisa D Wagner
Journal:  Thromb Haemost       Date:  2012-07-10       Impact factor: 5.249

4.  Fibrinolytic and ACE Inhibitory Activity of Nattokinase Extracted from Bacillus subtilis VITMS 2: A Strain Isolated from Fermented Milk of Vigna unguiculata.

Authors:  S Merlyn Keziah; C Subathra Devi
Journal:  Protein J       Date:  2021-10-05       Impact factor: 2.371

5.  Use of simultaneous angioplasty and in situ thrombolysis with a specialized balloon catheter for peripheral interventions.

Authors:  Shradha Rathi; Faisal Latif; J Emilio Exaire; Thomas A Hennebry
Journal:  J Thromb Thrombolysis       Date:  2008-11-06       Impact factor: 2.300

6.  [Acute limb ischemia from the general surgeon's point of view. How much knowledge of vascular surgery is necessary?].

Authors:  R Kopp; R Weidenhagen; H Hornung; K W Jauch; L Lauterjung
Journal:  Chirurg       Date:  2003-12       Impact factor: 0.955

Review 7.  Fibrinolytic Enzymes for Thrombolytic Therapy.

Authors:  Swaroop S Kumar; Abdulhameed Sabu
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

8.  Purification and characterization of mutant miniPlasmin for thrombolytic therapy.

Authors:  Xiaotao Lin; Yan Wang; Yanwen Zhang; Bing Huang; James J Lin; Scott J Hallock; Hong Yu; Hongwei Shao; Jing Yan; Bo Huang; Xuejun C Zhang; Wei Cao; Xueming Xu; Xinli Lin
Journal:  Thromb J       Date:  2013-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.